Literature DB >> 8958307

Tumor-specific deposition of immunoglobulin G and complement in papillary thyroid carcinoma.

S D Lucas1, A Karlsson-Parra, B Nilsson, L Grimelius, G Akerström, J Rastad, C Juhlin.   

Abstract

Despite its predilection for multifocal growth and regional metastasis, papillary thyroid carcinoma (PTC) is a clinically indolent malignancy with an exceptionally favorable long-term prognosis. Together with the often striking inflammatory reaction present in PTC, its quiescent behavior has been suggested to reflect the activation of a tumor-induced immune response. To examine this possibility, we have studied the deposition of immunoglobulins and complement in PTC tissue. Samples from 70 cases of neoplastic and autoimmune thyroid diseases, including PTC (n = 41), follicular, anaplastic, and medullary carcinomas (n = 12), follicular adenoma (n = 6), Graves' disease (n = 8), and Hashimoto's thyroiditis (n = 3) were analyzed immunohistochemically. Cellular deposits of immunoglobulin G (IgG), particularly subclasses IgG1 and IgG4, and complement factors C3d, C4d, and C5 were shown in up to 80% of the PTC cases, whereas the other thyroid diseases studied showed little or no cellular deposition. Nonneoplastic tissue of PTC-containing thyroid glands (n = 22) lacked staining for IgG in 50% of the cases, and 82% were devoid of complement. The results suggest a tumor-specific immune response in PTC with activation of the classical complement cascade.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8958307     DOI: 10.1016/s0046-8177(96)90346-9

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  29 in total

1.  Sublytic complement protects prostate cancer cells from tumour necrosis factor-α-induced cell death.

Authors:  L Liu; W Li; Z Li; M Kirschfink
Journal:  Clin Exp Immunol       Date:  2012-08       Impact factor: 4.330

2.  Plasma proteomic analysis of patients with squamous cell carcinoma of the uterine cervix.

Authors:  Dae Hoon Jeong; Hyoung Kyu Kim; Abd-Ei Bary Prince; Dae Sim Lee; Young Nam Kim; Jin Han; Ki Tae Kim
Journal:  J Gynecol Oncol       Date:  2008-09-30       Impact factor: 4.401

3.  Analysis of the interplay between methylation and expression reveals its potential role in cancer aetiology.

Authors:  Bugra Ozer; Ugur Sezerman
Journal:  Funct Integr Genomics       Date:  2016-11-07       Impact factor: 3.410

Review 4.  The dual role of complement in cancer and its implication in anti-tumor therapy.

Authors:  Ioannis Kourtzelis; Stavros Rafail
Journal:  Ann Transl Med       Date:  2016-07

5.  Complement Inhibition: A Novel Form of Immunotherapy for Colon Cancer.

Authors:  Stephanie Downs-Canner; Deepa Magge; Roshni Ravindranathan; Mark E O'Malley; Lily Francis; Zuqiang Liu; Z Sheng Guo; Natasa Obermajer; David L Bartlett
Journal:  Ann Surg Oncol       Date:  2015-08-20       Impact factor: 5.344

6.  Inhibition of decay-accelerating factor (CD55) attenuates prostate cancer growth and survival in vivo.

Authors:  Robert D Loberg; LaShon L Day; Rodney Dunn; Linda M Kalikin; Kenneth J Pienta
Journal:  Neoplasia       Date:  2006-01       Impact factor: 5.715

Review 7.  Targeting complement-mediated immunoregulation for cancer immunotherapy.

Authors:  Martin Kolev; Maciej M Markiewski
Journal:  Semin Immunol       Date:  2018-02-15       Impact factor: 11.130

8.  Down-regulation of CD55 and CD46 expression by anti-sense phosphorothioate oligonucleotides (S-ODNs) sensitizes tumour cells to complement attack.

Authors:  S Zell; N Geis; R Rutz; S Schultz; T Giese; M Kirschfink
Journal:  Clin Exp Immunol       Date:  2007-09-28       Impact factor: 4.330

9.  Complement Membrane Attack and Tumorigenesis: A SYSTEMS BIOLOGY APPROACH.

Authors:  Laurence D Towner; Richard A Wheat; Timothy R Hughes; B Paul Morgan
Journal:  J Biol Chem       Date:  2016-05-19       Impact factor: 5.157

Review 10.  The role of complement in tumor growth.

Authors:  Ruben Pio; Leticia Corrales; John D Lambris
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.